GlassScriptPhysician profile
Jeffrey Taffet
NPI 1699744052
$5,539.68
in general payments reported to CMS, 2019-2025
27 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $173 · 2021: $470 · 2022: $627 · 2023: $1,787 · 2024: $820 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,908.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,443.52 | 2021-2025 | |
| Glaxosmithkline, LLC. | $760.68 | 2021-2025 | Nucala |
| Stryker Corporation | $748.22 | 2019-2025 | Clarifix, Medline Industries, INC., Audion Et Dilation System |
| Genzyme Corporation | $672.50 | 2019-2025 | |
| Medtronic, INC. | $507.81 | 2023 | Propel, Stealthstation S8 Platform, Sinuva |
| Optinose US, INC. | $281.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $219.44 | 2019-2025 | Dupixent |
| Inspire Medical Systems, INC. | $129.37 | 2023 | Inspire |
| Hikma Pharmaceuticals USA | $128.10 | 2023-2025 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $97.24 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $89.90 | 2025 | |
| Neurent Medical Limited | $53.64 | 2022-2025 | Neuromark System, Neuromark Radiofrequency Console |
| Baudax Bio INC. | $43.90 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $38.70 | 2024 | Dupixent |
| Karl Storz Endoscopy-America | $37.45 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.47 | 2023 | Bridion |
| Merit Medical Systems INC | $30.65 | 2025 | Big60 Inflation Device |
| Ethicon US, LLC | $30.43 | 2022 | |
| Intersect Ent, INC. | $29.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2022 | |
| Baxter Healthcare | $25.79 | 2024 | Floseal |
| Amgen INC. | $23.49 | 2025 | Tezspire |
| Olympus America INC. | $19.57 | 2019 | |
| Smith+Nephew, INC. | $18.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.73 | 2025 | Tezspire |
| Acell, INC. | $15.36 | 2019 | |
| Horizon Therapeutics Plc | $14.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Taffet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.